Pulmonology

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.

The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Your daily dose of the clinical news you may have missed.

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.

The WAYFINDER trial is the first to demonstrate the positive impact of the thymic stromal lymphopoietin antagonist on steroid-dependent severe asthma.

Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

New clinical trial findings to be presented at ATS 2025 highlights the effectiveness of dupilumab in treating COPD and asthma.

Mepolizumab also cut annualized exacerbation rates by 21% across the full study cohort and by 31% in a subgroup of participants with chronic bronchitis only.

Researchers reported higher levels of perceived stress were associated with worse respiratory outcomes, particularly among individuals with severe COPD.

Telehealth visits in pediatric primary care were linked to lower antibiotic prescribing rates for respiratory infections compared with in-person visits.

The FDA has cleared TytoCare’s AI-powered Tyto Insights for detecting rhonchi, the third lung sound alongside wheeze and crackles.

Your daily dose of the clinical news you may have missed.

A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.

Five years after the COVID-19 pandemic was declared, the protean syndrome dubbed long COVID continues to affect millions; Greenspan is dedicated to helping.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

Some hospitals have EDs filled with patients and a number of states are reporting the 2024-2025 version of a COVID-19, flu, and RSV tripledemic.

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.